A $1Billion tax credit/grant program, part of the 2010 federal stimulus package, was intended to bolster the biotechnology industry during the current recession. The program was administered by the IRS and projects were qualified by the NIH. Therabron Therapeutics received a $244K federal tax grant through the Qualifying Therapeutic Discovery Project program for R&D expenses incurred in both 2009 and 2010. The company’s qualifying therapeutic project pertained to the development of recombinant human CC10 protein for the prevention of neonatal BPD, a form of chronic lung disease that develops in very premature infants.
- Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
- Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference
- Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
- Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences
- Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants